We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after February 22, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
Semi-live respiratory syncytial virus vaccine
METHOD FOR EXPRESSION OF HETEROLOGOUS PROTEINS USING A RECOMBINANT NEGATIVE-STRAND RNA VIRUS VECTOR
GENERATION OF VIROSOME PARTICLES